We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FY 21 Funding Levels are Not Going to Work for the FDA in FY 22, Says Industry Watcher
FY 21 Funding Levels are Not Going to Work for the FDA in FY 22, Says Industry Watcher
Continuing resolution (CR) funding for the FDA at fiscal 2021 levels denies the FDA increased funding as Congress intended, limits new program starts and makes it difficult for the agency to plan its policy, program and personnel needs.